The needs, challenges, and priorities of cell therapy developers have greatly evolved over the past decade. How can we continue this momentum to overcome existing obstacles and advance the cell therapy journey to commercialization?
At this digital meeting, global experts joined to share experiences, lessons, and insight into why the industry needs flexible, integrated, and connected solutions. This discussion examined key factors in the efficient manufacturing of critical cell therapies, including:
- Robust and reliant supply chains
- Digitally connected solutions
- Sustainable cryogenic ecosystems
Representatives from Cytiva’s cell therapy team also shared the latest products and services designed to enable a robust, automated, and effective cell therapy process.
Professor of Medicine, Director, Advanced Cellular Therapeutics Facility, Faculty Director, Cellular & Tissue based Processing cGMP Facility Hematology/Oncology Section, Dept. of Medicine
University of Chicago
Director of Operations, Research and Innovation
Leeds Teaching Hospitals NHS Trust
Application Specialist Leader
Field Application Scientist
In Partnership with Cytiva:
Cytiva is a global provider of technologies and services that help advance and accelerate the development and manufacture of therapeutics. Previously GE Healthcare Life Sciences, Cytiva’s diverse portfolio includes well-recognized brands such as ÄKTA, Amersham, Biacore, FlexFactory, HyClone, MabSelect, Whatman and Xcellerex. Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the delivery of transformative medicines to patients.
Visit cytiva.com for more.